Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer

• Main Authors: Paul M. Kuhn (Author), Gabriella C. Russo (Author), Ashleigh J. Crawford (Author), Aditya Venkatraman (Author), Nanlan Yang (Author), Bartholomew A. Starich (Author), Zachary Schneiderman (Author), Pei-Hsun Wu (Author), Thi Vo (Author), Denis Wirtz (Author), Efrosini Kokkoli (Author)
• Format: Book
• Published: MDPI AG, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Effectively utilizing MEK inhibitors in the clinic remains challenging due to off-target toxicity and lack of predictive biomarkers. Recent findings propose E-cadherin, a breast cancer diagnostic indicator, as a predictor of MEK inhibitor success. To address MEK inhibitor toxicity, traditional metho...